Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal microbiota transplant plus nivolumab in immunotherapy-refractory metastatic melanoma, MSI-high/dMMR tumors, and non-small cell lung cancer
MOH_2020-08-11_008813Phase 2Recruiting
- Sponsor
- Ella Therapeutics
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and fecal microbiome transplant in melanoma, microsatellite instability-high cancer, mismatch repair deficient solid tumor and 1 more (3 cohorts), sponsored by Ella Therapeutics. Started Mar 2020; status: recruiting.
02
Drugs
nivolumabfecal microbiome transplant
03
Conditions
melanomamicrosatellite instability-high cancermismatch repair deficient solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2020-08-11_008813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-11_008813.